Lunai Bioworks Inc

Lunai Bioworks Inc(RENB)财务数据

$1.420

+0.173 (+12.16%)收盘时

RENB 盈利能力与利润率

Evaluating the bottom line, Lunai Bioworks Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -46.10%, provide a clear picture of how effectively RENB converts its operational activities into shareholder value.

RENB 同业对比

In the context of the broader market, RENB competes directly with industry leaders such as BCTX and CVKD. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, RENB's gross margin of N/A stands against BCTX's N/A and CVKD's N/A. Such benchmarking helps identify whether Lunai Bioworks Inc is trading at a premium or discount relative to its financial performance.

Financials

FY2023Q1
0.00
Total Revenue
FY2025Q3
YoY:
-52.54%
-4.16M
Operating Profit
FY2025Q3
YoY:
-100.32%
189.18K
Net Income after Tax
FY2025Q3
YoY:
-100.00%
0.00
EPS - Diluted
FY2025Q3
YoY:
-43.64%
-1.49M
Free Cash Flow

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始